Nonsteroidal antiinflammatory drugs: A review

Journal of the American Animal Hospital Association

Volumn 41, Issue 5, 2005, Pages 298-309

  Curry, Stephen L ^a   Cogar, Steven M ^a   Cook, James L ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ACETYLSALICYLIC ACID; ACTIVATED CARBON; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; CARPROFEN; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DERACOXIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETODOLAC; ETOGESIC; HEPARIN; KETOPROFEN; LAXATIVE; LIPOXIN; LIPOXYGENASE; MANNITOL; MELOXICAM; NEW DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN; SUCRALFATE; TEPOXALIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VETERINARY DRUG; WARFARIN; ZUBRIN;

ANIMAL DISEASE; DOSE RESPONSE; DRUG CLASSIFICATION; DRUG COST; DRUG DOSE REGIMEN; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; GASTROINTESTINAL TOXICITY; HUMAN; INFLAMMATION; NEPHROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PEPTIC ULCER; PROSTAGLANDIN SYNTHESIS; REVIEW; THROMBOSIS;

ANIMALIA;

EID: 31844442507     PISSN: 15473317     EISSN: 15473317     Source Type: Journal    
DOI: 10.5326/0410298     Document Type: Review

References (71)

1. Adams HR, ed. Veterinary Pharmacology and Therapeutics. 8th ed. Ames: Iowa State University Press, 2001.
2. Weissmann G. The actions of NSAIDs. Hosp Pract 1991;26:60-76.
3. Bertolini A, Ottani A, Sandrini A. Dual acting anti-inflammatory drugs: a reappraisal. Pharmacol Res 2001;44:437-450.
4. Robinson DR. Eicosanoids, inflammation, and antiinflammatory drugs. Clin Exp Rheum 1989;7:S155-161.
5. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
6. Picot D, Loll PJ, Garavito RM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature 1994;367:234-249.
7. Griswold DE, Adams JL. Constitutive cyclooxygenase (COX-1) and inducible cyclooxygenase (COX-2): rationale for selective inhibition and progress to date. Med Res Rev 1996;16:181-206.
8. Donnelly MT, Hawkey CJ. Review article: COX-II inhibitors - a new generation of safer NSAIDs? Aliment Pharmacol Ther 1997;11:227-236.
9. Streppa HK, Jones CJ, Budsberg SC. Cyclooxygenase selectivity of nonsteroidal anti-inflammatory drugs in canine blood. Am J Vet Res 2002;63:91-94.
10. Cryer B, Feldman M. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-431.
11. Hochberg MC. NSAIDs: mechanisms and pathways of action. Hosp Pract 1989;24:185-198.
12. Brater DC. Clinical pharmacology of NSAIDs. J Clin Pharmacol 1988;28:518-523.
13. Aitken MM, Sanford J. Plasma levels following administration of sodium meclofenamate by various routes. Res Vet Sci 1975;19:241-244.
14. Golden BD, Abramson SB. Selective cyclooxygenase-2 inhibitors. Rheum Dis Clin North Am 1999;25:359-378.
15. Portanova JP, Zhang Y, Anderson GD, et al. Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J Exp Med 1996;184:883-891.
16. Wright JM. The double-edged sword of COX-2 selective NSAIDs. CMAJ 2002;167:1131-1137.
17. Mizuno H, Sakamoto C, Matsuda K. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology 1997;112:387-397.
18. Kirchner T, Aparicio B, Argentieri DC, et al. Effects of tepoxalin, a dual inhibitor of cyclooxygenase/5-lipoxygenase, on events associated with NSAID-induced gastrointestinal inflammation. Prostaglandins Leukot Essent Fatty Acids 1997;56:417-423.
19. Wallace JL, McKnight W, Reuter BK, et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. Gastroenterology 2000;119:706-714.
20. Lecomte M, Laneuville O, Ji C, et al. Acetylation of human prostaglandin endoperoxide synthase-2 (cyclooxygenase-2) by aspirin. J Biol Chem 1994;269:13207-13215.
21. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA, Med Sci, Boston, 1995;92:9475-9479.
22. Takano T, Clish CB, Gronert K, et al. Neutrophil-mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin Invest 1998;101:819-826.
23. Smith WL, Bell TG. Immunohistochemical localization of prostaglandin-forming cyclooxygenase in renal cortex. Am J Physiol 1978;235:F451-457.
24. Harris RC, McKanna JA, Akai Y, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1994;94:2504-2510.
25. Spangler RS. Cyclooxygenase 1 and 2 in rheumatic disease: implications for nonsteroidal anti-inflammatory drug therapy. Semin Arthritis Rheum 1996;26:435-446.
26. Bjorkman DJ. Current status of nonsteroidal anti-inflammatory drug (NSAID) use in the United States: risk factors and frequency of complications. Am J Med 1999;107:3S-10S.
27. Piper JM, Ray WA, Daugherty JR, et al. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-740.
28. Kawaguchi H, Pilbeam CC, Harrison JR, et al. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res 1995;313:36-46.
29. Jackson ML. Platelet physiology and platelet function: inhibition by aspirin. Compend Contin Educ Pract Vet 1987;9:627-638.
30. Plumb DC. Veterinary Drug Handbook. 4th ed. Ames: Iowa State University Press, 2002.
31. Short CR, Hsieh LC, Malbrough MS, et al. Elimination of salicylic acid in goats and cattle. Am J Vet Res 1990;51:1267-1270.
32. Davis LE, Westfall BA. Species differences in biotransformation and excretion of salicylate. Am J Vet Res 1972;33:1253-1262.
33. Burton BT, Bayer MJ, Barron L, et al. Comparison of activated charcoal and gastric lavage in the prevention of aspirin absorption. J Emerg Med 1984;1:411-416.
34. Villar D, Buck WB, Gonzalez JM. Ibuprofen, aspirin and acetaminophen toxicosis and treatment in dogs and cats. Vet Hum Toxicol 1998;40:156-162.
35. Humber LG. Etodolac: the chemistry pharmacology, metabolic disposition, and clinical profile of a novel anti-inflammatory pyranocarboxylic acid. Med Res Rev 1987;7:1-28.
36. Gervais F, Martel RR, Skamene E. The effect of the nonsteroidal anti-inflammatory drug etodolac on macrophage chemotaxis in vitro and in vivo. J Immunopharmacol 1984;6:205-214.
37. Cayen MN, Kraml M, Ferdinandi ES, et al. The metabolic disposition of etodolac in rats, dogs, and man. Drug Metab Rev 1981;12:339-362.
38. Budsberg SC, Johnston SA, Schwartz PD, et al. Efficacy of etodolac for the treatment of osteoarthritis of the hip joints in dogs. J Am Vet Med Assoc 1999;214:206-210.
39. Fry SW, Seeff LB. Hepatotoxicity of analgesics and anti-inflammatory agents. Gastroenterol Clin North Am 1995;24:875-905.
40. Klauss G, Giuliano EA, Moore CP, et al. Canine keratoconjunctivitis sicca associated with etodolac administration. Vet Ophthalmol 2003;6:361-362.
41. Davidson G. Pharm profile: etodolac. Compend Contin Educ Pract Vet 1999;21:494-495.
42. Fox SM, Johnston SA. Use of carprofen for the treatment of pain and inflammation in dogs. J Am Vet Med Assoc 1997;210:1493-1498.
43. Ricketts AP, Lundy KM, Seibel SB. Evaluation of selective inhibition of canine cyclooxygenase 1 and 2 by carprofen and other nonsteroidal anti-inflammatory drugs. Am J Vet Res 1998;59:1441-1446.
44. Lipscomb VJ, AliAbadi FS, Lees P, et al. Clinical efficacy and pharmacokinetics of carprofen in the treatment of dogs with osteoarthritis. Vet Rec 2002;150:684-689.
45. Buvanendran A, Kroin JS, Tuman KJ, et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor on pain management and recovery of function after knee replacement: a randomized controlled trial. JAMA 2003;290:2411-2418.
46. Clark TP, Chieffo C, Huhn JC, et al. The steady-state pharmacokinetics and bioequivalence of carprofen administered orally and subcutaneously in dogs. J Vet Pharmacol Ther 2003;26:187-192.
47. Schmitt M, Guentert TW. Biopharmaceutical evaluation of carprofen following single intravenous, oral, and rectal doses in dogs. Biopharm Drug Dispos 1990;11:585-594.
48. Kemmerer JM, Rubio FA, McClain RM, et al. Stereospecific assay and stereospecific disposition of racemic carprofen in rats. J Pharm Sci 1979;68:1274-1280.
49. Rubio F, Seawall S, Pocelinko R, et al. Metabolism of carprofen, a nonsteroid anti-inflammatory agent, in rats, dogs, and humans. J Pharm Sci 1980;69:1245-1253.
50. Verbeeck RK. Pharmacokinetic drug interactions with nonsteroidal anti-inflammatory drugs. Clin Pharmacokinet 1990;19:44-66.
51. MacPhail CM, Lappin MR, Meyer DJ, et al. Hepatocellular toxicosis associated with administration of carprofen in 21 dogs. J Am Vet Med Assoc 1998;212:1895-1901.
52. Julou L, Guyonnet JC, Ducrot R, et al. Ketoprofen (19.583 R.P.) (2-(3-benzoylphenyl)-propionic acid). Main pharmacological properties - outline of toxicological and pharmacokinetic data. Scand J Rheumatol Suppl 1976;1976:33-44.
53. Owens JG, Kamerling SG, Stanton SR, et al. Effects of pretreatment with ketoprofen and phenylbutazone on experimentally induced synovitis in horses. Am J Vet Res 1996;57:866-874.
54. Kubota T, Komatsu H, Kawamoto H, et al. Studies on the effects of anti-inflammatory action of benzoyl-hydrotropic acid (ketoprofen) and other drugs, with special reference to prostaglandin synthesis. Arch Int Pharmacodyn Ther 1979;237:169-176.
55. Handley DA, Cervoni P, McCray JE, et al. Preclinical enantioselective pharmacology of (R)- and (S)- ketorolac. J Clin Pharmacol 1998;38:25S-35S.
56. Schmitt M, Guentert TW. Biopharmaceutical evaluation of ketoprofen following intravenous, oral, and rectal administration in dogs. J Pharm Sci 1990;79:614-616.
57. Owens JG, Kamerling SG, Barker SA. Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis. J Vet Pharmacol Ther 1995;18:187-195.
58. Mathews KA. Non-steroidal anti-inflammatory analgesics: a review of current practice. J Vet Emerg Crit Care 2002;12:89-97.
59. Lemke KA, Runyon CL, Horney BS. Effects of preoperative administration of ketoprofen on whole blood platelet aggregation, buccal mucosal bleeding time, and hematologic indices in dogs undergoing elective ovariohysterectomy. J Am Vet Med Assoc 2002;220:1818-1822.
60. Skeith KJ, Dasgupta M, Lange R, et al. The influence of renal function on the pharmacokinetics of unchanged and acyl-glucuroconjugated ketoprofen enantiomers after 50 and 100 mg racemic ketoprofen. Br J Clin Pharmacol 1996;42:163-169.
61. Sancilio LF, Taylor MA, Mathur PP, et al. Interaction between warfarin and nonsteroidal anti-inflammatory drugs (NSAIDs) in rats. Life Sci 1985;36:1041-1050.
62. Wallace JM. Pharm profile: meloxicam. Compend Contin Educ Pract Vet 2003;15:64-65.
63. Doig PA, Purbrick KA, Hare JE, et al. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J 2000;41:296-300.
64. Mathews KA, Pettifer G, Foster R, et al. Safety and efficacy of preoperative administration of meloxicam, compared with that of ketoprofen and butorphanol in dogs undergoing abdominal surgery. Am J Vet Res 2001;62:882-888.
65. Wallace JL, McCafferty DM, Carter L, et al. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy? Gastroenterology 1993;105: 1630-1636.
66. Argentieri DC, Ritchie DM, Ferro MP, et al. Tepoxalin: a dual cyclooxygenase/5-lipoxogenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. J Pharmacol Exp Ther 1994;271:1399-1408.
67. Brideau C, Van Staden C, Chan CC. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. Am J Vet Res 2001;62:1755-1760.
68. Belch JJ. Eicosanoids and rheumatology: inflammatory and vascular aspects. Prostaglandins Leukot Essent Fatty Acids 1989;36:219-234.
69. Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygnease pathway. Biochemistry and relation to pathobiology in human diseases. N Engl J Med 1990;323:645-655.
70. Crooks SW, Stockley RA. Leukotriene B4. Int J Biochem Cell Biol 1998;30:173-178.
71. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population of elderly adults. Ann Intern Med 2005;142:1-10.